Comparable stake leader
Vuong Trieu
SEC ownership of Oncotelic Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000908259.
Disclosed value leader
Vuong Trieu
Comparable rows
0/7
Latest evidence
10 Jul 2026
- Public ticker
- OTLC on OTC
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Vuong Trieu
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
10 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000908259
- Issuer location
- Aguora Hills, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Oncotelic Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vuong Trieu
Disclosed value leader
Vuong Trieu
Comparable rows
0/7
Latest evidence
10 Jul 2026
3/4/5
Highest disclosed value: $5,475,932
7 rows are not safely comparable across share classes.
Quick read
Vuong Trieu has the largest disclosed position value at $5.48M.
0 of 7 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vuong Trieu's linked filing trail.
Disclosed position value
Top 2
Vuong Trieu
$5.48M
Amit B. Shah
$18.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-7 of 7 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vuong Trieu |
3/4/5
CHAIRMAN AND CEO, Director, 10%+ Owner
|
—
mixed-class rows
|
$5,475,932
117,787,723 shares
mixed-class rows
|
+$36,832 | 10 Jul 2026 |
| Amit B. Shah |
3/4/5
CFO
|
—
mixed-class rows
|
$18,941
1,078,593 shares
mixed-class rows
|
+$1,000 | 10 Jul 2026 |
| Saran Saund |
3/4/5
CBO
|
—
mixed-class rows
|
—
676,500 shares
mixed-class rows
|
— | 10 Jul 2026 |
| Anthony E. Maida III |
3/4/5
DIRECTOR AND CMO - TRANS. MED., Director
|
—
mixed-class rows
|
—
601,500 shares
mixed-class rows
|
— | 10 Jul 2026 |
| Steven W. King |
3/4/5
Director
|
—
mixed-class rows
|
—
500,250 shares
mixed-class rows
|
— | 10 Jul 2026 |
| David Diamond |
3/4/5
Director
|
—
class O/S missing
|
—
451,467 shares
|
— | 08 Jul 2021 |
| Seymour Howard Fein |
3/4/5
CRO/CMO
|
—
class O/S missing
|
—
250 shares
|
— | 10 Jul 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$37,832.
Buys
$37,832
Insiders: 2
Sells
$0
Insiders: 0
Net
+$37,832
Shares: +850,759
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 850,759
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 850,759 | 0 | $37,832 | $0 | +$37,832 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-7 of 7 reporting-owner rows connected to Oncotelic Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
7
Largest Forms 3/4/5 holder
Vuong Trieu
Net 12M change
+$37,832
Latest report
10 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Vuong Trieu | CHAIRMAN AND CEO, Director, 10%+ Owner | $5,475,932 | +$36,832 | +0.68% | Mixed | 10 Jul 2026 |
| Amit B. Shah | Cfo | $18,941 | +$1,000 | +5.6% | Filing P/S | 10 Jul 2026 |
| David Diamond | Director | Mixed | 08 Jul 2021 | |||
| Anthony E. Maida III | DIRECTOR AND CMO - TRANS. MED., Director | Mixed | 10 Jul 2026 | |||
| Saran Saund | Cbo | Mixed | 10 Jul 2026 | |||
| Steven W. King | Director | Mixed | 10 Jul 2026 | |||
| Seymour Howard Fein | Cro/Cmo | Mixed | 10 Jul 2026 |
Recent insider transactions for Oncotelic Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Seymour Howard Fein | OTLC | Restricted stock Units | Award | 250 | 250 | 10 Jul 2026 | Direct | |||
| Steven W. King | OTLC | Restricted stock Units | Award | 250 | 250 | 10 Jul 2026 | Direct | |||
| Anthony E. Maida III | OTLC | Restricted stock Units | Award | 1,500 | 1,500 | 10 Jul 2026 | Direct | |||
| Saran Saund | OTLC | Restricted stock Units | Award | 1,500 | 1,500 | 10 Jul 2026 | Direct | |||
| Amit B. Shah | OTLC | Restricted stock Units | Award | 1,500 | 1,500 | 10 Jul 2026 | Direct | |||
| Vuong Trieu | OTLC | Restricted stock Units | Award | 2,000 | 2,000 | 10 Jul 2026 | Direct | |||
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.26% | $10,344 | $0.0431 | 240,000 | 94,124,319 | 01 Jul 2026 | Direct |
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.12% | $5,175 | $0.0450 | 115,000 | 93,884,319 | 24 Jun 2026 | Direct |
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.08% | $3,375 | $0.0450 | 75,000 | 93,769,319 | 23 Jun 2026 | Direct |
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.07% | $2,925 | $0.0450 | 65,000 | 93,694,319 | 22 Jun 2026 | Direct |
| Amit B. Shah | OTLC | Common Stock | Purchase | 5.57% | $1,000 | $0.0500 | 20,000 | 378,837 | 22 Jun 2026 | Direct |
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.26% | $10,693 | $0.0446 | 239,759 | 93,629,319 | 17 Jun 2026 | Direct |
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.1% | $4,320 | $0.0450 | 96,000 | 93,389,560 | 15 Jun 2026 | Direct |
| Vuong Trieu | OTLC | Series A Convertible Preferred Stock | Award | 108.9% | 4,426 | 8,491 | 22 Jan 2026 | Direct | ||
| Vuong Trieu | OTLC | Series A Convertible Preferred Stock | Award | 4,065 | 4,065 | 17 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.